Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis

被引：2
|
作者：
Pogosova, Nana [1 ]
Bosch, Jacqueline
Bhatt, Deepak L. [4 ]
Fox, Keith A. A. [5 ]
Connolly, Stuart J. [2 ,3 ,6 ]
Alings, Marco [7 ]
Verhamme, Peter [8 ]
Muehlhofer, Eva [9 ]
Shestakovska, Olga [2 ]
Yusuf, Salim [2 ,3 ,6 ]
Eikelboom, John W. [2 ,3 ,6 ]
机构：
[1] Natl Med Res Ctr Cardiol, Moscow, Russia
[2] Populat Hlth Res Inst, Hamilton, ON, Canada
[3] McMaster Univ, Hamilton, ON, Canada
[4] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA
[5] Univ Edinburgh, Ctr Cardiovasc Sci, Edinburgh, Midlothian, Scotland
[6] Hamilton Hlth Sci, Hamilton, ON, Canada
[7] Amphia Ziekenhuis & WCN, Utrecht, Netherlands
[8] Univ Leuven, Leuven, Belgium
[9] Bayer AG, Wuppertal, Germany
来源：
CIRCULATION | 2022年 / 145卷 / 25期
关键词：
aspirin; coronary artery disease; peripheral artery disease; rivaroxaban; venous thromboembolism;
D O I：
10.1161/CIRCULATIONAHA.122.059405
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1875 / 1877
页数：3
相关论文
共 50 条
  • [41] Safety, Efficacy and Pharmacokinetics of Ritonavir 400mg/Saquinavir 400mg Twice Daily plus Rifampicin Combined Therapy in HIV Patients with Tuberculosis
    Valeria Cavalcanti Rolla
    Maria A da Silva Vieira
    Douglas Pereira Pinto
    Maria C Lourenço
    Carlos da Silva de Jesus
    Mariza Gonçalves Morgado
    Milton Ferreira Filho
    Eduardo Werneck-Barroso
    Clinical Drug Investigation, 2006, 26 : 469 - 479
  • [42] Efficacy, side effect profile, and pharmacokinetics of once vs. twice daily dosing of 800 mg of ribavirin plus intron a in the treatment of naive chronic HCV patients.
    Ghalib, R
    Clark, C
    Dadbeh, P
    Clark, C
    Ankoma-Sey, V
    Brass, C
    HEPATOLOGY, 1999, 30 (04) : 369A - 369A
  • [43] Aspirin Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis Among Patients With Post-Thrombotic Syndrome: The Multicenter, Multinational, Randomized, Open-Label ARIVA Trial
    Barco, Stefano
    Jalaie, Houman
    Sebastian, Tim
    Wolf, Simon
    Fumagalli, Riccardo M.
    Lichtenberg, Michael
    Zeller, Thomas
    Erbel, Christian
    Schlager, Oliver
    Kucher, Nils
    CIRCULATION, 2025, 151 (12) : 835 - 846
  • [44] Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients
    Castagnetti, Fausto
    Breccia, Massimo
    Gugliotta, Gabriele
    Martino, Bruno
    D'Adda, Mariella
    Stagno, Fabio
    Carella, Angelo Michele
    Avanzini, Paolo
    Tiribelli, Mario
    Trabacchi, Elena
    Visani, Giuseppe
    Gobbi, Marco
    Salvucci, Marzia
    Levato, Luciano
    Binotto, Gianni
    Capalbo, Silvana Franca
    Bochicchio, Maria Teresa
    Soverini, Simona
    Cavo, Michele
    Martinelli, Giovanni
    Alimena, Giuliana
    Pane, Fabrizio
    Saglio, Giuseppe
    Rosti, Gianantonio
    Baccarani, Michele
    HAEMATOLOGICA, 2016, 101 (10) : 1200 - 1207
  • [45] COST-EFFECTIVENESS OF RIVAROXABAN 2.5MG IN COMBINATION WITH ASPIRIN IN TREATMENT OF PATIENTS WITH CORONARY ARTERY DISEASE (CAD) OR PERIPHERAL ARTERY DISEASE (PAD) IN GREECE
    Kalogeropoulou, M.
    Gkouvitsos, I
    Barlogiannis, T.
    Bowrin, K.
    Briere, J. B.
    Millier, A.
    Karabis, A.
    VALUE IN HEALTH, 2019, 22 : S555 - S555
  • [46] Levofloxacin 500 mg once daily versus cefuroxime 250 mg twice daily in patients with acute exacerbations of chronic obstructive bronchitis:: clinical efficacy and exacerbation-free interval
    Petitpretz, Patrick
    Chone, Claudie
    Tremolieres, Francois
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 30 (01) : 52 - 59
  • [47] Efficacy and tolerability of twice-daily ciprofloxacin 750mg in the treatment of patients with acute exacerbations of chronic bronchitis and pneumonia
    Pryka, R
    Kowalsky, S
    Haverstock, D
    CLINICAL THERAPEUTICS, 1998, 20 (01) : 141 - 155
  • [48] Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis
    Piedra, Katrina
    Peterson, Tim
    Tan, Carlyn
    Orozco, Jennifer
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Lesokhin, Alexander
    Shah, Urvi
    Lu, Sydney
    Patel, Dhwani
    Derkach, Andriy
    Wilkins, Cy R.
    Korde, Neha
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (01) : 105 - 109
  • [49] The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease (vol 142, pg 40, 2020)
    Steffel, J.
    CIRCULATION, 2020, 142 (01)
  • [50] Fondaparinux 1.5 mg in renally-impaired patients, fondaparinux 2.5 mg in patients with normal renal function in the prevention of venous thromboembolism after major orthopedic surgery, the same exposure?
    Delavenne, X.
    Zufferey, P.
    Mismetti, P.
    Laporte, S.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2011, 25 : 103 - 103
12345